Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review

Sphingosine 1‐phosphate receptor modulators in multiple sclerosis treatment: A practical review

Abstract Four sphingosine 1‐phosphate (S1P) receptor modulators (fingolimod, ozanimod, ponesimod, and siponimod) are approved by the US Food and Drug Administration for the treatment of multiple sclerosis. This review summarizes efficacy and safety data on these S1P receptor modulators, with an emph...

Full description

Bibliographic Details
Main Authors: Patricia K. Coyle, Mark S. Freedman, Bruce A. Cohen, Bruce A. C. Cree, Clyde E. Markowitz
Format: Article
Language:English
Published: Wiley 2024-04-01
Series:Annals of Clinical and Translational Neurology
Online Access:https://doi.org/10.1002/acn3.52017

Similar Items

Similar Items